Autolus Therapeutics Files 8-K for Regulation FD Disclosure

TL;DR

**Autolus Therapeutics plc filed a standard 8-K for Regulation FD disclosure on February 13, 2024, making new information public.**

AI Summary

Autolus Therapeutics plc filed an 8-K on February 13, 2024, to report an event occurring on the same date. The filing, identified by accession number 0001193125-24-033690, indicates a Regulation FD Disclosure and the inclusion of Financial Statements and Exhibits. This ensures public dissemination of information by the London-based biotechnology company, Autolus Therapeutics plc.

Why It Matters

An 8-K filing for Regulation FD Disclosure means Autolus Therapeutics plc is making public material non-public information to ensure fair and equal access for all investors. This prevents selective disclosure and maintains market transparency.

Risk Assessment

Risk Level: low — This 8-K is a standard procedural filing for Regulation FD disclosure, which aims to ensure fair information dissemination, and does not inherently signal high risk.

Key Players & Entities

• Autolus Therapeutics plc (company) — filer

FAQ

From the Filing

0001193125-24-033690.txt : 20240213 0001193125-24-033690.hdr.sgml : 20240213 20240213160602 ACCESSION NUMBER: 0001193125-24-033690 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20240213 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 24625770 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 d785281d8k.htm 8-K 8-K 00-0000000 false 0001730463 0001730463 2024-02-13 2024-02-13     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024     Autolus Therapeutics plc (Exact name of registrant as specified in its Charter)       England and Wales   001-38547   Not applicable (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices) (Zip Code) (44) 20 3829 6230 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, par value $0.000042 per share   AUTL   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 7.01 Regulation FD Disclosure. On February 13, 2024, Autolus Therapeutics plc (the “ Company ”) posted an updated corporate presentation to its website. A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934